Indoco Remedies Limited INDOCO NSEPHARMA

Q: What is the current share price of Indoco Remedies Limited (INDOCO)?

As of 2026-09-08 04:53 IST, Indoco Remedies Limited (INDOCO) trades at ₹262.51 on NSE. Its 52-week range is ₹164.00 to ₹308.60.

Q: What is the market capitalisation of INDOCO?

Indoco Remedies Limited (INDOCO) has a market capitalisation of ₹2,423.06 Cr on NSE.

Q: What is the P/E ratio of INDOCO?

INDOCO trades at a trailing price-to-earnings (P/E) ratio of -24.53. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 1.99.

Q: Does INDOCO pay a dividend?

Indoco Remedies Limited (INDOCO) currently offers a dividend yield of 0.09%.

Q: What is the return on equity (ROE) of INDOCO?

INDOCO has a return on equity (ROE) of -10.13%. Its return on capital employed (ROCE) is 1.02%.

Q: Is INDOCO a good stock to buy?

This page provides a data-driven analysis of Indoco Remedies Limited (INDOCO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.indoco.com

Company Profile ↓

₹262.51

-10.34% 1Y

Mkt Cap₹2,423.06 Cr

P/E-24.53

P/B1.99

Div. Yield0.09%

52W High₹308.60

52W Low₹164.00

Book Value₹101.76

EPS (TTM)₹-10.70

Company Overview

Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, the company offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. Additionally, it provides contract research services, such as custom chemical synthesis of molecules and intermediates; process chemistry research and development; non-infringing process designing and scale up; and analytical method development, validation, impurity characterization, and polymorphic studies, solutions, as well as intellectual property management. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of ₹1,792.94 Cr (+9.2% YoY); net profit ₹-95.15 Cr.
Trailing 12 Months Year-on-year growth — revenue +9.2%.
5-Year Trend Long-term compounding — revenue CAGR 3.0%, profit CAGR -55.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	3.02%
1 Year:	9.24%

Compounded Profit Growth

5 Years:	-55.63%
1 Year:	-

Stock Price Performance

1 Year:	-10.34%
6 Months:	+32.34%
3 Months:	+27.52%
1 Month:	+18.34%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 68% of range

₹164.00 ₹308.60

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)64.59 · Neutral

Price Performance

1M+18.34%

3M+27.52%

6M+32.34%

1Y-10.34%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

NSE TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -55.6% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-24.53

Industry PE

41.64

Forward P/E

21.61

PEG Ratio

Book Value

₹101.76

Price to Book

1.99

P/S

1.09

EV/EBITDA

18.42

Dividend Yield

0.09%

Growth (CAGR)

Revenue 5Y

3.02%

Profit 5Y

-55.63%

Revenue (YoY)

9.24%

Earnings (YoY)

Profitability & Returns

ROCE

1.02%

ROE

-10.13%

ROA

-3.67%

Profit Margin

-5.31%

Op Margin

0.86%

Gross Margin

69.78%

EPS (Latest Qtr)

₹7.09

EPS (TTM)

₹-10.70

Balance Sheet & Liquidity

Debt/Equity

1.16

Quick Ratio

0.75

Current Ratio

1.13

Debt

₹1,089.75 Cr

Total Assets

₹2,593.27 Cr

Current Assets

₹1,193.35 Cr

Working Capital

₹140.81 Cr

Ownership

Promoter Holding

60.89%

Chg in Prom Hold

2.03%

FII / Inst Holding

19.93%

Chg in FII Hold

0.33%

Financial Snapshot

Enterprise Value

₹2,423.06 Cr

Total Revenue (TTM)

₹1,792.94 Cr

EBITDA

₹142.19 Cr

Free Cash Flow

₹101.00 Cr

Operating Cash Flow

₹226.35 Cr

Shares Outstanding

₹9.23 Cr

Gross Margin

69.78%

Payout Ratio

60.61%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	INDOCO Indoco Remedies Limited NSEPHARMA	262.51	-24.53	₹2,423.06 Cr	0.09%	1.02%	-10.13%	3.02%	-55.63%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,899.00	39.73	₹4.56 L Cr	0.82%	17.94%	13.74%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	9,100.00	94.06	₹2.42 L Cr	0.36%	18.96%	15.32%	10.98%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,857.00	75.99	₹1.64 L Cr	0.77%	9.05%	25.79%	13.27%	20.22%
5	APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA	8,650.00	64.10	₹1.24 L Cr	0.22%	19.20%	20.48%	14.85%	33.34%
6	LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA	684.90	236.17	₹1.19 L Cr	0.00%	7.21%	5.65%	35.38%	66.99%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,120.00	22.36	₹1.13 L Cr	0.09%	19.04%	18.59%	16.55%	36.99%
8	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,385.00	28.85	₹1.12 L Cr	0.88%	14.86%	11.27%	7.23%	11.45%
9	LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA	1,840.00	111.85	₹99,333.61 Cr	0.13%	19.53%	16.77%	3.77%	4.00%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	428.00 Cr	426.00 Cr	482.00 Cr	459.00 Cr	450.00 Cr	431.00 Cr	433.00 Cr	411.00 Cr	-	430.86 Cr	471.83 Cr	434.34 Cr	455.90 Cr	466.22 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	-	134.97 Cr	145.34 Cr	120.42 Cr	141.01 Cr	158.05 Cr
Gross Profit	-	-	-	-	-	-	-	-	-	295.89 Cr	326.49 Cr	313.92 Cr	314.89 Cr	308.17 Cr
Operating Expenses	363.00 Cr	365.00 Cr	410.00 Cr	397.00 Cr	401.00 Cr	384.00 Cr	392.00 Cr	399.00 Cr	-	308.06 Cr	315.69 Cr	314.42 Cr	297.67 Cr	301.68 Cr
Operating Income	47.00 Cr	41.00 Cr	50.00 Cr	39.00 Cr	23.00 Cr	20.00 Cr	11.00 Cr	-17.00 Cr	-	-12.17 Cr	10.80 Cr	-50.00 L	17.22 Cr	6.49 Cr
EBITDA	65.00 Cr	61.00 Cr	71.00 Cr	63.00 Cr	49.00 Cr	48.00 Cr	40.00 Cr	12.00 Cr	-	19.16 Cr	43.28 Cr	26.34 Cr	53.41 Cr	140.54 Cr
Interest Expense	9.00 Cr	8.00 Cr	8.00 Cr	10.00 Cr	12.00 Cr	14.00 Cr	18.00 Cr	16.00 Cr	-	26.12 Cr	24.56 Cr	25.64 Cr	45.92 Cr	28.29 Cr
Pretax Income	39.00 Cr	34.00 Cr	46.00 Cr	23.00 Cr	33.00 Cr	7.00 Cr	-5.00 Cr	-31.00 Cr	-	-36.66 Cr	-13.53 Cr	-31.31 Cr	-25.00 Cr	77.72 Cr
Tax Provision	13.26 Cr	9.86 Cr	11.04 Cr	7.13 Cr	10.89 Cr	5.18 Cr	-5.35 Cr	2.48 Cr	-	-31.00 L	-4.32 Cr	-1.86 Cr	-1.32 Cr	12.28 Cr
Net Income	26.00 Cr	24.00 Cr	35.00 Cr	16.00 Cr	22.00 Cr	2.00 Cr	-10.00 Cr	-28.00 Cr	-	-35.79 Cr	-7.93 Cr	-29.79 Cr	-21.64 Cr	64.99 Cr
Diluted EPS	2.80	2.65	3.81	1.77	2.46	0.28	-1.04	-2.86	-	-3.94	-1.00	-3.20	-2.57	7.09

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	854.00 Cr	1,005.00 Cr	1,071.00 Cr	1,041.00 Cr	968.00 Cr	1,107.00 Cr	1,242.00 Cr	-	1,640.05 Cr	1,788.22 Cr	1,641.29 Cr	1,792.94 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	539.31 Cr	582.10 Cr	498.18 Cr	541.74 Cr
Gross Profit	-	-	-	-	-	-	-	-	1,100.73 Cr	1,206.12 Cr	1,143.11 Cr	1,251.20 Cr
Operating Expenses	689.00 Cr	834.00 Cr	914.00 Cr	906.00 Cr	892.00 Cr	983.00 Cr	1,017.00 Cr	-	903.10 Cr	1,063.26 Cr	1,157.69 Cr	1,235.85 Cr
Operating Income	119.00 Cr	110.00 Cr	94.00 Cr	67.00 Cr	5.00 Cr	52.00 Cr	152.00 Cr	-	197.64 Cr	142.86 Cr	-14.58 Cr	15.35 Cr
EBITDA	166.00 Cr	171.00 Cr	157.00 Cr	135.00 Cr	77.00 Cr	123.00 Cr	225.00 Cr	-	287.15 Cr	262.59 Cr	105.70 Cr	142.19 Cr
Interest Expense	11.00 Cr	12.00 Cr	6.00 Cr	24.00 Cr	21.00 Cr	26.00 Cr	22.00 Cr	-	23.75 Cr	34.93 Cr	66.23 Cr	122.25 Cr
Pretax Income	110.00 Cr	99.00 Cr	91.00 Cr	48.00 Cr	-9.00 Cr	29.00 Cr	132.00 Cr	-	192.79 Cr	135.80 Cr	-74.37 Cr	-106.51 Cr
Tax Provision	26.40 Cr	16.83 Cr	13.65 Cr	7.20 Cr	6.21 Cr	4.64 Cr	39.60 Cr	-	50.54 Cr	38.79 Cr	3.58 Cr	-7.81 Cr
Net Income	83.00 Cr	82.00 Cr	77.00 Cr	41.00 Cr	-3.00 Cr	24.00 Cr	93.00 Cr	-	142.25 Cr	98.46 Cr	-73.74 Cr	-95.15 Cr
Diluted EPS	8.99	8.89	8.36	4.47	-0.31	2.62	10.10	-	15.42	10.67	-8.46	-10.70

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	846.00 Cr	941.00 Cr	1,197.00 Cr	1,238.00 Cr	1,258.00 Cr	1,272.00 Cr	1,315.00 Cr	-	1,658.20 Cr	2,144.73 Cr	2,429.91 Cr	2,593.27 Cr
Current Assets	-	-	-	-	-	-	-	-	813.57 Cr	954.67 Cr	1,001.34 Cr	1,193.35 Cr
Cash & Equivalents	-	-	-	-	-	-	-	-	10.92 Cr	14.86 Cr	12.10 Cr	25.93 Cr
Inventory	-	-	-	-	-	-	-	-	325.99 Cr	353.06 Cr	419.35 Cr	405.21 Cr
Receivables	-	-	-	-	-	-	-	-	350.94 Cr	406.20 Cr	352.41 Cr	489.17 Cr
Total Liabilities	-	-	-	-	-	-	-	-	629.95 Cr	1,034.23 Cr	1,411.54 Cr	1,661.16 Cr
Current Liabilities	-	-	-	-	-	-	-	-	424.51 Cr	612.33 Cr	807.99 Cr	1,052.54 Cr
Long Term Debt	-	-	-	-	-	-	-	-	143.50 Cr	351.73 Cr	533.20 Cr	516.02 Cr
Total Debt	97.00 Cr	140.00 Cr	280.00 Cr	282.00 Cr	296.00 Cr	262.00 Cr	267.00 Cr	-	332.85 Cr	671.95 Cr	993.57 Cr	1,089.75 Cr
Total Equity	518.00 Cr	576.00 Cr	651.00 Cr	675.00 Cr	660.00 Cr	679.00 Cr	769.00 Cr	-	1,028.25 Cr	1,109.90 Cr	1,022.00 Cr	939.28 Cr
Shares Outstanding	-	-	-	-	-	-	-	-	9.22 Cr	9.22 Cr	9.22 Cr	9.23 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	109.00 Cr	112.00 Cr	89.00 Cr	123.00 Cr	132.00 Cr	123.00 Cr	82.00 Cr	-	178.83 Cr	155.39 Cr	90.76 Cr	226.35 Cr
Investing Cash Flow	-88.00 Cr	-111.00 Cr	-171.00 Cr	-135.00 Cr	-104.00 Cr	-56.00 Cr	-67.00 Cr	-	-208.17 Cr	-432.52 Cr	-259.79 Cr	-87.38 Cr
Financing Cash Flow	-20.00 Cr	-2.00 Cr	132.00 Cr	-39.00 Cr	-16.00 Cr	-64.00 Cr	-30.00 Cr	-	22.80 Cr	122.39 Cr	168.62 Cr	-133.09 Cr
Capital Expenditure	-89.00 Cr	-97.00 Cr	-189.00 Cr	-138.00 Cr	-93.00 Cr	-59.00 Cr	-76.00 Cr	-	-207.25 Cr	-425.99 Cr	-258.43 Cr	-125.35 Cr
Free Cash Flow	20.00 Cr	15.00 Cr	-100.00 Cr	-15.00 Cr	39.00 Cr	64.00 Cr	6.00 Cr	-	-28.42 Cr	-270.60 Cr	-167.67 Cr	101.00 Cr
Net Change in Cash	1.00 Cr	-0	50.00 Cr	-51.00 Cr	12.00 Cr	3.00 Cr	-14.00 Cr	-	-6.54 Cr	3.31 Cr	-41.00 L	5.88 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	67.1%	67.4%	69.6%	69.8%
Operating Margin %	13.9%	10.9%	8.8%	6.4%	0.5%	4.7%	12.2%	-	12.1%	8.0%	-0.9%	0.9%
Net Margin %	9.7%	8.2%	7.2%	3.9%	-0.3%	2.2%	7.5%	-	8.7%	5.5%	-4.5%	-5.3%
ROE %	16.0%	14.2%	11.8%	6.1%	-0.5%	3.5%	12.1%	-	13.8%	8.9%	-7.2%	-10.1%
ROCE %	-	-	-	-	-	-	-	-	16.0%	9.3%	-0.9%	1.0%

Shareholding Pattern

Insiders

60.89%

Institutions

19.93%

Public Float

50.96%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INDOCO

Google News Mon, 07 Sep 2026

News by CNBC TV18 on TradingView, 2026-09-07 — cnbctv:e9009f58a094b:0 - TradingView

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5zWld1b0drYVBFaXRGYVQ0MFpRTFFjd3BkYlhya1htMk1xWFZOdy1HRHltTkhQRDR6M2FpMjdwVkFBMTZUYUNWUTdYazlDOEs0T2hHYmlaN3czYWFPYjlDdHpVbzZ0ZkE?oc=5" target="_blank">News by CNBC TV18 on Trading…

Google News ue, 28 Jul 2026

Earnings call transcript: Indoco Remedies Q1 2026 revenue miss sends shares down 8% - Investing.com

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOSjNKeFNNV0NPQjVBelVvMEtwRUQ2Y3RaU2lreUhPVldXemdoeFVIMjdyeFJNN3dlbFdVakZOd3VLYVVPVVo4elZkWWxCeG95bnFwQkp1eTRhX0xPZzlUYXVsaHNWbnJxUG8yVUs5MmFyZzdLOU9qQzVjenFhN3JKcjZYVUl3dkYzZ0hCY3…

Google News Fri, 31 Jul 2026

Here's What Analysts Are Forecasting For Indoco Remedies Limited (NSE:INDOCO) After Its First-Quarter Results - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQQkdqdUYwNERFU1VHVFk0VHA3TnhkR3JoUjJzWGNDUHdrX1dtWDNMOUxXdndrNzllX3JrZ3kxMWE1YlB1SlJxV3ZoRFpjaWh0OGFaY1VKcEpXSzFvcW05ZENraG80Nkg4TGlvWldrbldqd0JSa0FYVjRfeVJCSzFCTlJqUTlzMEFTX053RF…

Google News Wed, 02 Sep 2026

Indoco Remedies Ltd. Share Price Rise and Valuation View - Univest

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxOOWdnUnppVVFIYkZGazdGWlpsbDlhZUY4dlRHVTZmaFdXQS1FZ1lPQ0c4MF9DSHlma0x1WHlyeGlJTWRpQ3JhMmswWTg2aHBkS3c5WTNMcDdKMnBpVnlUcGY1SkFKRlJ0YmZsb0xDMXlhLTk4XzEzSVI2SjFXOGZtVC1n?oc=5" target=…

Google News hu, 27 Aug 2026

Indoco Remedies Ltd. Key Financial Ratios – Valuation, Profitability & More - Value Research

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPWFZvcWxzVXAxM04tN2xnQUE4OVc1VEVyX1IwSzBHdEVvZk42d0VidjNUVFRaYnM5M2dtcnBma1dGTHpIWmFDS0JLNTlNUHJhVUx3N3ZrM3ZyQzBUZGVySThKeWcwLU14UzhBaVp5S3U0SU5oVmg5bXhBMkhjdE5GeXhhbzBxbUE?oc=5" …

Google News ue, 01 Sep 2026

Indoco Remedies promoters buy 4,000 shares in open market on Sept 1 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPb0xkVTVjcTdPTnlJQ0J0bWxmZHJQOW5PaV96ZUt1YVdGZFFYbG9PRnpQQWJBNWg2UnN5OUNTeE1lRmN0bjQ2SW9KdXFSYklMUGpCQl93bFhyT0lkYlUxY3JmYlhka0FYR05ZSXcwZmoyWUExN2VOU2hERmR6RDF6eWpHcndibk9XWG1fcl…

INDOCO — Frequently Asked Questions

What is the current share price of Indoco Remedies Limited (INDOCO)?

As of 2026-09-08 04:53 IST, Indoco Remedies Limited (INDOCO) trades at ₹262.51 on NSE. Its 52-week range is ₹164.00 to ₹308.60.

What is the market capitalisation of INDOCO?

Indoco Remedies Limited (INDOCO) has a market capitalisation of ₹2,423.06 Cr on NSE.

What is the P/E ratio of INDOCO?

INDOCO trades at a trailing price-to-earnings (P/E) ratio of -24.53. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 1.99.

Does INDOCO pay a dividend?

Indoco Remedies Limited (INDOCO) currently offers a dividend yield of 0.09%.

What is the return on equity (ROE) of INDOCO?

INDOCO has a return on equity (ROE) of -10.13%. Its return on capital employed (ROCE) is 1.02%.

Is INDOCO a good stock to buy?

This page provides a data-driven analysis of Indoco Remedies Limited (INDOCO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks

Indoco Remedies Limited INDOCO NSEPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Analyst View

Latest News

News by CNBC TV18 on TradingView, 2026-09-07 — cnbctv:e9009f58a094b:0 - TradingView

Earnings call transcript: Indoco Remedies Q1 2026 revenue miss sends shares down 8% - Investing.com

Here's What Analysts Are Forecasting For Indoco Remedies Limited (NSE:INDOCO) After Its First-Quarter Results - simplywall.st

Indoco Remedies Ltd. Share Price Rise and Valuation View - Univest

Indoco Remedies Ltd. Key Financial Ratios – Valuation, Profitability & More - Value Research

Indoco Remedies promoters buy 4,000 shares in open market on Sept 1 - scanx.trade

INDOCO — Frequently Asked Questions

What is the current share price of Indoco Remedies Limited (INDOCO)?

What is the market capitalisation of INDOCO?

What is the P/E ratio of INDOCO?

Does INDOCO pay a dividend?

What is the return on equity (ROE) of INDOCO?

Is INDOCO a good stock to buy?

Explore More